Henrik Daub
Scientific Advisory Board
Medical Science
Denator
Sweden
Biography
Dr. Henrik Daub serves as Senior Vice President Science & Technology at Evotec Munich, overseeing the development and application of proteomics technologies in drug and biomarker research. He received his PhD from the Max Planck Institute for Biochemistry in Martinsried, for the discovery of fundamental signal transduction mechanisms. As a group leader at Max Planck Institute for Biochemistry, his research focused towards chemical proteomics and quantitative phosphoproteomics. Dr. Daub was a founder of Kinaxo, a biotech company specializing on high-end proteomics services, which was later acquired by Evotec.
Research Interest
His research interests lie in Healthcare and Medical Sciences. He is the Editor-in-Chief Member of many peer reviewed journals and his area of expertise credits him with many publications in national and international journals. He is committed to highest standards of excellence and it proves through his authorship of many books.
